Amir T Fathi

7PUBLICATIONS
109CO-AUTHORS
Gene and molecular therapyGene expression (incl. microarray and other genome-wide approaches)Medical molecular engineering of nucleic acids and proteinsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 02, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Dec 17, 2025
Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.

Kai Yu, Laura W Dillon, Jesse M Tettero

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

|Apr 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.

Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari

|Feb 17, 2025
Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy.

Catherine Gutierrez Moore, Anthony Stein, Amir T Fathi

|Apr 04, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.

Amir T Fathi, Haesook T Kim, Robert J Soiffer

Pageof 2

Frequent Collaborators

2 joint publications

Gail J Roboz

2 joint publications

Ghayas C Issa

2 joint publications

Harry P Erba

2 joint publications

Eunice S Wang